XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Consolidated Balance Sheet Details (Tables)
6 Months Ended
Jun. 30, 2022
Consolidated Balance Sheet [Abstract]  
Summary of Accrued Expenses

Accrued expenses consisted of the following (in thousands):

 

 

 

June 30,

 

 

December 31,

 

 

 

2022

 

 

2021

 

Accrued research and development costs

 

$

6,756

 

 

$

3,893

 

Accrued clinical trial costs

 

 

2,853

 

 

 

1,025

 

Other accrued liabilities

 

 

1,800

 

 

 

2,529

 

Accrued related party liabilities

 

 

74

 

 

 

175

 

Total accrued expenses

 

$

11,483

 

 

$

7,622